RxDoctor Payments DataLook up a doctor →

John Wittman, MD

Neurology · Richmond, VANPI 1366412892

Payments from drug & device makers

$75,113in general payments, 2019–2025

Across 1,127 payments — averaging $66.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$18K
  • UCB SA$14K
  • SK Life Science, Inc.$12K
  • AbbVie$9K
  • UCB, Inc.$4K
  • Biogen$2K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$2,1303%
  • Speaking & faculty fees$30,94851%
  • Travel & lodging$3,6906%
  • Food & beverage$24,06939%
  • Education$4291%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.52$18,447
UCB SA4$13,847
SK Life Science, Inc.66$12,158
AbbVie(2 entities)107$8,624
UCB, Inc.197$3,917
Biogen72$2,077
Ceribell, Inc.7$1,438
Sunovion Pharmaceuticals Inc.33$963
AstraZeneca(2 entities)34$906
Novartis59$897
Sanofi22$798
Neurelis, Inc.28$629
Jazz Pharmaceuticals Inc.18$597
Amgen(2 entities)25$552
Livanova USA, Inc.15$521
Greenwich Biosciences, Inc.14$458
Genentech USA, Inc.19$444
EMD Serono, Inc.23$433
Amneal Pharmaceuticals LLC21$430
Teva Pharmaceuticals USA, Inc.13$387
Lilly USA, LLC22$374
Grifols USA, LLC16$363
Lundbeck LLC20$362
Harmony Biosciences LLC12$326
Inspire Medical Systems, Inc.2$324
Pfizer19$310
Bristol Myers Squibb27$303
TG Therapeutics, Inc.12$279
Biohaven Pharmaceuticals, Inc.9$271
MDD US Operations, LLC13$267
Argenx US, Inc.8$237
Avadel CNS Pharmaceuticals, LLC3$207
Banner Life Sciences, LLC7$170
ANI Pharmaceuticals, Inc.7$166
Sumitomo Pharma America, Inc.9$164
E.r. Squibb & Sons, L.L.C.2$149
Insightec,inc1$136
Biohaven Pharmaceutical Holding Company Ltd.5$125
Supernus Pharmaceuticals, Inc.7$119
Catalyst Pharmaceuticals, Inc.6$119
Axsome Therapeutics, Inc.7$118
CSL Behring6$117
Acadia Pharmaceuticals Inc6$116
Mallinckrodt Hospital Products Inc.4$115
Neurocrine Biosciences, Inc.7$113
Kyowa Kirin, Inc.5$97
Merz Pharmaceuticals, LLC3$76
Impel Pharmaceuticals Inc.4$70
Merz North America, Inc.2$69
Medtronic1$66
Avanir Pharmaceuticals, Inc.4$63
Johnson & Johnson(2 entities)3$61
Neuropace, Inc.1$61
Adamas Pharmaceuticals, Inc.4$60
Alnylam Pharmaceuticals Inc.3$53
Acorda Therapeutics, Inc3$50
Upsher-smith Laboratories LLC2$41
Corium, LLC2$40
Vanda Pharmaceuticals Inc.2$36
Vertical Pharmaceuticals, LLC2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,113 in reported general payments places this provider in the 85th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$113,004
Medicare patients
847
Services billed
1,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FinteplaFenfluramine Hcl23$393,718
WakixPitolisant Hcl14$221,395
BriviactBrivaracetam117$181,417
XcopriCenobamate90$180,167
EpidiolexCannabidiol (Cbd)37$168,393
AptiomEslicarbazepine Acetate78$142,369
CopaxoneGlatiramer Acetate13$74,599
Rufinamide31$67,687
FycompaPerampanel45$59,307
VimpatLacosamide38$50,858
Lamictal XrLamotrigine25$43,686
KeppraLevetiracetam19$31,487
Lacosamide244$31,469
Lamotrigine ErLamotrigine65$23,046
BanzelRufinamide13$22,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Fintepla, Briviact, Vimpat, Nayzilam$3,917$647,758197 claims
Harmony Biosciences LLCWakix$326$221,39514 claims
SK Life Science, Inc.Xcopri$12,158$180,16790 claims
Sunovion Pharmaceuticals Inc.Aptiom$963$142,36978 claims
Eisai Inc.Fycompa, Banzel$18,447$81,86958 claims
Teva Pharmaceuticals USA, Inc.Copaxone$387$74,59913 claims
UCB SAKeppra$13,847$31,48719 claims
PfizerNurtec Odt, Dilantin$310$31,40156 claims
Neurelis, Inc.Valtoco$629$20,59919 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$430$4,07121 claims
Upsher-smith Laboratories LLCTopiramate$41$3,237149 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 neurology providers in Virginia.

Other neurology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →